4,186 Charles River Laboratories International, Inc. $CRL Shares Sold by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 69.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,826 shares of the medical research company’s stock after selling 4,186 shares during the quarter. Pekin Hardy Strauss Inc.’s holdings in Charles River Laboratories International were worth $539,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CRL. Physician Wealth Advisors Inc. raised its position in shares of Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 55 shares during the period. Continuum Advisory LLC purchased a new position in shares of Charles River Laboratories International during the 2nd quarter valued at $30,000. IFP Advisors Inc boosted its holdings in Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after buying an additional 106 shares during the period. Compass Wealth Management LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth $69,000. Finally, Activest Wealth Management increased its stake in Charles River Laboratories International by 25.9% in the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after buying an additional 57 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $337.91 on Friday. The firm has a market cap of $16.19 billion, a price-to-earnings ratio of 371.33, a P/E/G ratio of 3.14 and a beta of 1.36. The firm has a fifty day moving average price of $305.71 and a 200 day moving average price of $225.19. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $379.63. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.04 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.12. The company had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. Charles River Laboratories International’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.43 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.44 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Shannon Parisotto sold 3,714 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total value of $1,038,657.24. Following the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,344,325.62. The trade was a 43.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares in the company, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 102,299 shares of company stock worth $31,050,863. 1.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CRL shares. TD Cowen boosted their price objective on Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, September 25th. Jefferies Financial Group upped their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Morgan Stanley increased their target price on Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Zacks Research downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $308.17.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support.

The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions.